Halozyme is a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapies that target the tumor microenvironment. Its lead proprietary program, the investigational drug PEGPH20, applies a unique approach to targeting solid tumors, potentially providing increased tumor access for co-administered cancer therapies. By breaking down potential barriers to cancer, PEGPH20 may help make existing treatments more effective allowing therapies to reach the tumor. 
In addition to the Company's proprietary product portfolio, Halozyme has value-driving partnerships with leading pharmaceutical companies including Roche, Pfizer, Janssen, Baxalta, AbbVie and Lilly for its ENHANZE drug delivery technology platform, which enables biologics and small molecule compounds currently administered intravenously to be delivered subcutaneously. This technology may also allow for more rapid delivery of therapies that are already delivered subcutaneously. 

Show more
Type
Public
HQ
San Diego, US
Founded
1998
Size (employees)
259 (est)
Halozyme Therapeutics was founded in 1998 and is headquartered in San Diego, US
Report incorrect company information

Halozyme Therapeutics Office Locations

Halozyme Therapeutics has an office in San Diego
San Diego, US (HQ)
11388 Sorrento Valley Road
Show all (1)
Report incorrect company information

Halozyme Therapeutics Financials and Metrics

Halozyme Therapeutics Financials

Halozyme Therapeutics's revenue was reported to be $146.69 m in FY, 2016 which is a 8.6% increase from the previous period.
USD

Revenue (Q1, 2018)

30.9 m

Gross profit (Q1, 2018)

27.8 m

Gross profit margin (Q1, 2018), %

90.1%

Net income (Q1, 2018)

(27.5 m)

EBIT (Q1, 2018)

(23.7 m)

Market capitalization (15-May-2018)

2.8 b

Closing share price (15-May-2018)

19.7

Cash (31-Mar-2018)

98 m

EV

2.9 b
Halozyme Therapeutics's current market capitalization is $2.8 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

54.8 m75.3 m135.1 m146.7 m

Revenue growth, %

37%79%9%

Cost of goods sold

6.2 m22.7 m29.2 m33.2 m

Gross profit

48.6 m52.6 m105.8 m113.5 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Revenue

16 m12 m18.4 m14.6 m18.7 m43.4 m20.8 m42.5 m33.3 m31.9 m29.6 m33.8 m30.9 m

Cost of goods sold

682.7 k5.5 m5.9 m5.1 m6.5 m8.1 m6.2 m7.8 m8.3 m9.1 m7.5 m7.8 m3.1 m

Gross profit

15.3 m6.4 m12.5 m9.5 m12.2 m35.2 m14.6 m34.7 m25 m22.7 m22 m26 m27.8 m

Gross profit Margin, %

96%54%68%65%65%81%70%82%75%71%74%77%90%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

27.4 m61.4 m43.3 m66.8 m

Accounts Receivable

9.1 m9.1 m32.4 m15.7 m

Inventories

6.2 m6.4 m9.5 m14.6 m

Current Assets

95.2 m161.3 m171.8 m256.5 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

17.5 m76.6 m56.1 m46.4 m44.3 m67.8 m71.5 m69.1 m61.2 m61.2 m45.2 m114.7 m98 m

Accounts Receivable

24.5 m11 m12.9 m8.3 m7.7 m9.7 m8.4 m25.5 m23.2 m17.7 m12.5 m14.5 m26.6 m

Inventories

3.8 m6.8 m7.1 m6.9 m7.5 m7.7 m11.1 m10.3 m10.8 m12.9 m14.3 m15.2 m4.4 m

Current Assets

102.8 m190.9 m175.6 m158.6 m153.3 m168.4 m153.1 m297 m284.3 m272.6 m222.4 m340.8 m484.5 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(83.5 m)(68.4 m)(32.2 m)(103 m)

Depreciation and Amortization

1.2 m1.8 m1.7 m2.4 m

Inventories

(3.5 m)(236 k)(3.1 m)(5.1 m)

Accounts Payable

7.9 m(816 k)13.9 m(244 k)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(19.3 m)(26.5 m)(16.3 m)(20.3 m)(15.1 m)3 m(24.5 m)(19.8 m)(26.9 m)(28.9 m)(32.9 m)(27.5 m)

Depreciation and Amortization

566 k

Inventories

7.1 m6.9 m7.5 m7.7 m11.1 m10.3 m10.8 m12.9 m14.3 m752 k

Accounts Payable

3.9 m4.3 m3.3 m4.1 m4.4 m6.2 m3.7 m4.6 m3.1 m(12.6 m)
USDY, 2018

EV/EBIT

-123.2 x

EV/CFO

-131.8 x

Financial Leverage

1.9 x
Show all financial metrics
Report incorrect company information